» Authors » Theodoros Androutsakos

Theodoros Androutsakos

Explore the profile of Theodoros Androutsakos including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 40
Citations 292
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Komninaka V, Flevari P, Ntelaki E, Yfanti E, Androutsakos T, Ntanasis-Stathopoulos I, et al.
J Clin Med . 2024 Jan; 13(2). PMID: 38256595
Modifications of the hemoglobin (Hb) structure in regions involving the regulation of oxygen transport may lead to an increased oxygen affinity for the hemoglobin molecule and impaired oxygen delivery to...
12.
Karagiannakis D, Karakousis N, Androutsakos T
Biomedicines . 2024 Jan; 12(1). PMID: 38255164
In cirrhotic patients, non-selective b-blockers (NSBBs) constitute the reference treatment of choice as monotherapy or combined with band ligation for the prevention of first variceal bleeding and rebleeding, respectively. Furthermore,...
13.
Dimitriadis K, Katelani S, Pappa M, Fragkoulis G, Androutsakos T
J Pers Med . 2023 Dec; 13(12). PMID: 38138902
Hepatitis B virus (HBV) infection is a worldwide medical issue with significant morbidity and mortality, as it is the main cause of chronic liver disease and hepatocellular carcinoma (HCC). Both...
14.
Komninaka V, Flevari P, Karkaletsis G, Androutsakos T, Karkaletsi T, Ntanasis-Stathopoulos I, et al.
Diseases . 2023 Nov; 11(4). PMID: 37987272
We describe two cases of thalassemia intermedia (TI) patients with the presence of Gaucher-like cells in hematopoietic tissue biopsies, raising diagnostic dilemmas. The first is a 56-year-old female with bone...
15.
Zachou M, Flevari P, Nasiri-Ansari N, Varytimiadis C, Kalaitzakis E, Kassi E, et al.
Eur J Clin Pharmacol . 2023 Nov; 80(1):127-150. PMID: 37938366
Purpose: Non-alcoholic fatty liver disease (NAFLD) has become a leading cause of liver disease, affecting 30% of the global population. NAFLD prevalence is particularly high in obese individuals and patients...
16.
Katelani S, Fragoulis G, Bakasis A, Pouliakis A, Nikiphorou E, Atzeni F, et al.
Rheumatology (Oxford) . 2023 Oct; 62(SI3):SI252-SI259. PMID: 37871924
Objective: The objective of this study was to assess the possibility of HBV reactivation (HBVr) in patients with RA under anti-IL-6 treatment. Methods: Using PubMed, Scopus and EMBASE, we performed...
17.
Vallilas C, Papadakos S, Androutsakos T, Pergaris A, Sarantis P, Apostolidi E, et al.
Am J Case Rep . 2023 Oct; 24:e939862. PMID: 37812585
BACKGROUND Desmoid tumors are a fibroblastic proliferation of soft tissues, with an extreme inclination for local dissemination and recurrence. Surgical excision is the usual treatment choice, with data regarding pharmaceutical...
18.
Androutsakos T, Dimitriadis K, Revenas K, Vergadis C, Papadakis D, Sakellariou S, et al.
Dig Dis . 2023 Aug; 41(6):913-921. PMID: 37611545
Introduction: A variety of liver disorders are associated with characteristic histopathological findings that help in their diagnosis and treatment. However, percutaneous liver biopsy (PLB) is prone to limitations and complications....
19.
Androutsakos T, Mouziouras D, Katelani S, Psichogiou M, Sfikakis P, Protogerou A, et al.
Viruses . 2023 Jun; 15(6). PMID: 37376673
The arterial pathology and mechanisms of increased cardiovascular disease (CVD) risk in HCV-infected individuals are not yet clear. The aim of this study was to identify types of arterial pathology...
20.
Toutoudaki K, Dimakakou M, Androutsakos T
Vaccines (Basel) . 2023 Feb; 11(2). PMID: 36851329
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19), has led to a pandemic with more than 6.5 million deaths worldwide. Patients with liver cirrhosis (PWLC) are...